Web-based Archive of RIVM Publications
Not a member yet
15852 research outputs found
Sort by
Mycoplasma pneumoniae carriage in children with recurrent respiratory tract infections is associated with a less diverse and altered microbiota.
No full textMother-to-infant microbiota transmission and infant microbiota development across multiple body sites.
No full textScreening for Clostridioides difficile colonization at admission to the hospital: a multi-centre study.
No full textBudget impact analysis of two treatment approaches for hepatitis C in Malaysia through the use of voluntary and compulsory licensing options.
No full textThe role of algal EPS in reducing the combined toxicity of BPA and polystyrene nanoparticles to the freshwater algae Scenedesmus obliquus.
No full text
Correction: Hand hygiene improvement of individual healthcare workers: results of the multicentre PROHIBIT study.
No full textPredictive Value of c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users.
No full textPharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening in primary care, with SLCO1B1 c.521T>C as a risk factor for statin-induced adverse drug reactions. The focus was on changes in therapy as a proxy for adverse drug reactions observed in statin-users in a population-based Dutch cohort. In total, 1136 statin users were retrospectively genotyped for the SLCO1B1 c.521T>C polymorphism (rs4149056) and information on their statin dispensing was evaluated as cross-sectional research. Approximately half of the included participants discontinued or switched their statin treatment within three years. In our analyses, we could not confirm an association between the SLCO1B1 c.521T>C genotype and any change in statin therapy or arriving at a stable dose sooner in primary care. To be able to evaluate the predictive values of SLCO1B1 c.521T>C genotype on adverse drug reactions from statins, prospective data collection of actual adverse drug reactions and reasons to change statin treatment should be facilitated
